Pathway-level analysis revealed an overall trend toward normalization of AD-associated dysregulation after nemolizumab treatment, suggesting systemic immunomodulatory effects beyond itch control.
← all excerpts
Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab.
1
—
—